世联博研(北京)科技有限公司 主营:Flexcell细胞力学和regenhu细胞3D生物打印机销售技术服务: 美国Flexcell品牌FX-5000T细胞牵张应力加载培养系统,FX-5K细胞显微牵张应力加载培养系统,Tissue Train三维细胞组织培养与测试系统,FX-5000C三维细胞组织压应力加载培养系统,STR-4000细胞流体剪切应力加载培养系统,德国cellastix品牌Optical Stretcher高通量单细胞牵引应变与分析系统 Regenhu品牌3D discovery细胞友好型3D生物打印机,piuma细胞纳米压痕测试分析、aresis多点力学测试光镊,MagneTherm细胞肿瘤电磁热疗测试分析系统
服务电话: 010-67529703
主营产品: Flexcell细胞力学和regenhu细胞3D生物打印机销售技术服务: 美国Flexcell品牌FX-5000T细胞牵张应力加载培养系统,FX-5K细胞显微牵张应力加载培养系统,Tissue Train三维细胞组织培养与测试系统,FX-5000C三维细胞组织压应力加载培养系统,STR-4000细胞流体剪切应力加载培养系统,德国cellastix品牌Optical Stretcher高通量单细胞牵引应变与分析系统 Regenhu品牌3D discovery细胞友好型3D生物打印机,piuma细胞纳米压痕测试分析、aresis多点力学测试光镊,MagneTherm细胞肿瘤电磁热疗测试分析系统
联系我们

Dimscan细胞毒性检测系统(Cytotoxicity Assay System)

  • 如果您对该产品感兴趣的话,可以
  • 产品名称: Dimscan细胞毒性检测系统(Cytotoxicity Assay System)
  • 产品型号:Dimscan
  • 产品展商:Dimscan,bioimagingsolutions
  • 产品文档:无相关文档
简单介绍

DIMSCAN是用于在组织培养板中定量的相对细胞数半自动数字图像显微术系统。使用荧光素二乙酸酯(FDA)通过DIMSCAN测定细胞毒性测定法中,染料在活细胞选择性地累积,利用集落形成测定法,可以实现动态范围在4至7天内的生长曲线。 (1)活细胞的相对数目是通过测算荧光素二乙酸酯(FDA)的荧光强度,削减由背景荧光的阈值和由曙红所终止的不可存活的细胞的荧光值进行测量。 (2)可以使用含6至384个孔的矩形培养板,对于96孔板平均扫描时间为6分钟。 (3)系统采用了基于自相关函数的自动聚焦功能以*大限度地提高了系统的自动化的程度。 (4)相关程序存储重新扫描过程中的图像,并在用户扫描结束时显示出来,至今进行新的扫描过程。 (5)具有操作简便、准确、灵敏、重复性好等优点,细胞数量在1, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000和10

产品描述

A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplate

DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测



图1 DIMSCAN观测系统外观

2、系统亮点概述 
DIMSCAN是用于在组织培养板中定量的相对细胞数半自动数字图像显微术系统。使用荧光素二乙酸酯(FDA)通过DIMSCAN测定细胞毒性测定法中,染料在活细胞选择性地累积,利用集落形成测定法,可以实现动态范围在4至7天内的生长曲线。

(1)活细胞的相对数目是通过测算荧光素二乙酸酯(FDA)的荧光强度,削减由背景荧光的阈值和由曙红所终止的不可存活的细胞的荧光值进行测量。 
(2)可以使用含6至384个孔的矩形培养板,对于96孔板平均扫描时间为6分钟。 
(3)系统采用了基于自相关函数的自动聚焦功能以*大限度地提高了系统的自动化的程度。 
(4)相关程序存储重新扫描过程中的图像,并在用户扫描结束时显示出来,至今进行新的扫描过程。 
(5)具有操作简便、准确、灵敏、重复性好等优点,细胞数量在1, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000和10000 每个培养孔,测量8个重复,细胞数量与荧光强度呈良好的线性关系,线性相关系数为0.9996746375
DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图2细胞TC-71(尤因氏肉瘤)3天,20000细胞

DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图3 96孔板测试系统荧光测量线性(r2 = 0.9996746375) 
3、适用范围 
(1)细胞毒性试验,通过DIMSCAN测量集落形成可以实现动态范围在4至7天内的生长曲线。

DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测

DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图4细胞毒性试验
Cell line TC-71 (Ewing's sarcoma), day 3, 20000 cells
Treated with 4-HPR + n-oleylethanolamine (nOE), 1:1 (0-12 um both)

(2)荧光扫描图象处理 
DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图5 图象阈值处理(左边:原始图像;右边:处理后的二值图像)

3)建立细胞荧光预览缩略图 
DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图6 培养板单孔细胞荧光预览缩略图
4)其他用途 
**测定(**、病毒、**、病原体)和蛋白质组检测;核酸,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测

4、参数 
倒置荧光显微镜:Microscope: Olympus IX50 inverted microscope

步进电动平移台:Prior Pro Scan, 步进电机200步/转; 250微步/整步; S曲线加速
(stepper motors 200 steps/revolution; 250 microsteps/full step; S-curve acceleration)

CCD相机: QImaging Retiga Exi
CCD分辨率:1024/768
拥有内部冷却功能 
像素混合模式:1-4
(CCD resolution 1024/768;internal cooling;binning modes available: 1-4)

配置英特尔酷睿2双核处理器以上的计算机 
基本配置: 
奔腾III 800 MHz 或者更高;256 MB RAM或更高; 
集成了IEEE1394火线接口的PCI卡 
(Pentium III 800 MHz, 256 MB RAM; IEEE1394 FireWire interface PCI card)

操作系统(Operating System: Windows 2000,XP


DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图7 细胞培养板扫描过程图示

5、使用方法 
(1)DIMSCAN用户界面组成 
程序窗口的主要部分包括:
控制面板 
——完整的板图片 
——支持通过选定孔导航阶段 
——任意孔扫描选择 
——扫描完成该孔含有重建图像 
——严重扫描孔重新扫描已启用

现场摄像头控制 
——实时图像流 
——相机控制,包括阈值 
缩略图 
——个别培养孔扫描高分辨率图像重建
DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图8 DIMSCAN 半自动荧光数字图像显微处理系统观察界面


(2)主要操作流程 
根据具体说明书进行。

6、系统组成部分 
倒置荧光显微镜,步进电机扫描器,扫描控制器,CCD像机(软件Qimaging Microimager Ⅱ),微型计算机。
DIMSCAN自动荧光数字图像显微处理系统,DIMSCAN细胞毒性测定系统,DIMSCAN活细胞的相对数测定系统,DIMSCAN**测定(**、病毒、**、病原体)系统,DIMSCAN蛋白质组检测系统,DIMSCAN核酸测定系统,DNA和基因组检测;快速即时的临床诊断;食品和环境检测;**检测
图9 DIMSCAN观测系统的组成模块


参考文献

  1. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates. Cytometry 24:204-213. 1996

  2. Krejsa J, Frgala F, Alfaro P, Reynolds CP. DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates. 2002 AACR Annual Meeting (poster). 2002

  3. Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds. Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines. 2003 AACR Annual Meeting. 2003

  4. Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds. The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents.. 2004 AACR Annual Meeting. 2004

  5. Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P.. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.. Methods Mol.Med., 110: 139-153. 2005

  6. Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.. Mol Cancer Ther, 6(3):886-97. 2007

ABSTRCT FOR DIMSCAN

DIMSCAN is a semi-automatic digital image microscopy system for quantitating relative cell numbers in tissue culture plates. Cytotoxicity assays measured by DIMSCAN using fluorescein diacetate (FDA), a dye accumulating selectively in viable cells, can achieve a 4 log dynamic range at 4 to 7 days and correlate with colony forming assays. The system consists of an inverted fluorescence microscope, stepper motor scanning stage, the stage controller, CCD camera and a microcomputer running the main application, which controls stage movement and processes CCD camera images. Relative numbers of viable cells are determined by evaluating FDA fluorescence intensity, with background fluorescence eliminated by digital thresholding and a quenching of florescence in non-viable cells with the vital stain Eosin Y. The current system uses Olympus IX50 inverted florescence microscope, a Prior motorized stage, a Qimaging Microimager II camera, and a Pentium III computer running Windows 2000. Rectangular plates can be employed with number of wells ranging from 6 to 96 wells per plate. Average scan time for a 96 well plate is 6 minutes.

apers on DIMSCAN development

Authors

Paper name

Published in

Year

Proffitt RT, Tran JV, Reynolds CP

A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates

Cytometry24:204-213

1996

Krejsa J, Frgala F, Alfaro P, Reynolds CP

DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates

2002 AACR Annual Meeting (poster)

2002

Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds

Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines

2003 AACR Annual Meeting

2003

Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds

The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents.

2004 AACR Annual Meeting

2004

Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P.

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Methods Mol.Med., 110: 139-153

2005

Frgala T, Kalous O, Proffitt RT, Reynolds CP

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.

Mol Cancer Ther,6(3):886-97

2007


[ Back to Top ]

Papers using DIMSCAN:

Authors

Paper name

Published in

Year

Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P

Comparison of 13-cis- retinoic acid to trans-retinoic acid using human neuroblastoma cell lines

Advances in Neuroblastoma Research 4, Evans A, Biedler JL, Brodeur G, D'Angio GJ, Nakagawara A (eds.), New York: John Wiley & Sons, 237-244

1994

Keshelava N, Seeger RC, Reynolds CP

Drug resistance phenotype of neuroblastoma cell lines established at diagnosis and at relapse after induction chemotherapy or bone marrow transplantation

European J Cancer33:2002-2006

1997

Anderson CP, Tsai JM, Chan WW, Liu RM, Forman HJ, Reynolds CP

Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines

European J Cancer 33:2016-2019

1997

Keshelava N, Seeger RC, Groshen S, Reynolds CP

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy

Cancer Research 58:5396-5405

1998

Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds G P

Depletion of Glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis

Experimental Cell Research246:183-192

1999

Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP

N-(4-hydroxypheynl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines

J Natl Cancer Inst 91:1138-1146

1999

Keshelava N, Groshen S, Reynolds CP

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

Cancer Chemotherapy and Pharmacology45:1-8

2000

Chen RL, Reynolds CP, Seeger RC, Cabot MC, Reynolds CP

Neutrophils are cytotoxic and growth inhibiting for neuroblastoma cells with anti-GD2 antibody but without cytotoxicity can be growth stimulating

Clinical Immunol Immunother48:603-612

2000

Maurer BJ, Cabot MC, Reynolds CP

Synergism of N-(4-hydroxyphenyl)retinamide cytotoxicity by modulators of ceramide metabolism in solid tumor cell lines

J Natl Cancer Inst 92:1897-1908

2000

Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ

Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide

Medical Pediatric Oncology35:597-602

2000

Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche CJ, Reynolds CP

Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines

Cancer Research 61:6185-6193

2001

Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP

Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line

J Pediat Hematol Oncol 23:500-505

2001

Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC

Enhanced expression and activation of Mac-1(CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity

Blood 99:4166-4173

2002

O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes

Leukemia 16:902-910

2002

Anderson C, Reynolds CP

Cytotoxicity of buthionine sulfoximine (BSO) and melphalan/BSO in combination for neuroblastoma cell lines derived after myeloablative therapy

Bone Marrow Transplantation30:135-140

2002

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith

Testing of New Agents in Childhood Cancer Preclinical Models : Meeting Summary

Clinical Cancer Research8:3646-3657

2002

Bo Yang, Nino Keshelava, Clarke P. Anderson, and C. Patrick Reynolds

Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine

Cancer Research 63:1520-1526

2003

Nino Keshelava, Denice Tsao-Wei, and C. Patrick Reynolds

Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p531

Clinical Cancer Research9:3492-3502

2003

Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.

In vitro testing of chemosensitivity in physiological hypoxia.

Methods Mol.Med., 110: 87-100

2005

Reynolds, C. P. and Maurer, B. J.

Evaluating response to antineoplastic drug combinations in tissue culture models.

Methods Mol.Med., 110: 173-183

2005

Yang, B. and Reynolds, C. P.

Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.

Clin.Cancer Res., 11: 2774-2780

2005

Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Tony Ng T, Reynolds CP, Triche TJ, Sorensen PHB

E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.

Cancer Research, 67: 3094-3105

2007

Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA

Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer,(In Press).

2007

Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP

Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents.

J National Cancer Institute, 99:1107-19

2007

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA

Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer.,(In Press)

2007

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Blood, 110:205-2066

2007

Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB

Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer,(In Press)

2007

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA

Initial testing of dasatinib by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer,(In Press)

2007

Reynolds CP, Kang MH, Keshelava N, Mauer BJ

Assessing combinations of cytotoxic agents using leukemia cell lines.

Current Drug Targets,8:765-771

2007


[ Back to Top ]

Clinical Trials Enabled by DIMSCAN Testing:


Authors

Paper name

Published in

Year

Villablanca JG, Avramis V, Khan A, Matthay KK, Ram say NKC, Seeger RC, Reynolds CP

Phase I trial of 13-cis-retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT)

J Clinical Oncology13:894-901

1995

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP

Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid

New Eng J Med 341:1165-1173

1999

Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krail M, Reynolds CP

Phase I trial of oral [N- (-4-hydroxyphenyl) retinamide] (4-HPR) in children with resistant/recurrent solid tumors: A Children's Cancer Group Study (CCG 09709)

Proc Amer Soc Clin Oncol21:398a

J Clinical Oncology24:3423-3430

2002


2006

Anderson CP, Robert Seeger RC, Bailey H, Reynolds CP

Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB)

Proc Amer Soc Clin Oncol21 :298a

2002

New Approaches to Neuroblastoma Therapy

N2002-01: A Phase I Study of High-Dose Pyrazoloacridine (PZA) (NSC 366140) Supported with Autologous Hematopoietic Stem Cell Rescue in Children with Recurrent or Resistant Neuroblastoma.

Closed

?

Children's Oncology Group

ANBL0321: A Phase II Study of Fenretinide in Children with Recurrent/Resistant High Risk Neuroblastoma.

Ongoing

?

New Approaches to Neuroblastoma Therapy

N99-02: A Phase I trial of BSO + L-PAM and Stem Cell Support.

Ongoing

?

Norris Cancer Center

A Phase II trial of Fenretinide in Recurrent Ovarian Cancer.

Proc Amer Soc Clin Oncol23:461

Proc Amer Soc Clin Oncol25: Abst 5555

2004


2007

California Cancer Consortium

A Phase II trial of Fenretinide in Prostate Cancer.

Ongoing

?

California Cancer Consortium

A Phase I trial of Intravenous Fenretinide in Hematological Malignancies.

Ongoing

?

California Cancer Consortium

A phase I trial of intravenous fenretinide in solid tumors

Ongoing

?

California Cancer Consortium

A phase II trial of fenretinide in asymptomatic rising PSA prostate cancer

Completed

?

New Approaches to Neuroblastoma Therapy

N2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254)

Ongoing

?

Therapeutic Advances in Childhood Leukemia

TACL 2005-001: A phase I/II trial of ABT-751 combined with dexamethasone, PEG-asparaginase, and doxorubicin in relapsed acute lymphoblastic leukemia (ALL)

Ongoing

?

Therapeutic Advances in Childhood Leukemia

TACL 2005-003: Bortezomib with chemotherapy for relapsed childhood ALL.

Ongoing

?

Therapeutic Advances in Childhood Leukemia

TACL 2006-001: IV Fenretinide in Relapsed ALL, AML or NHL.

Ongoing

产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
Copyright@ 2003-2024  世联博研(北京)科技有限公司版权所有      电话:13466675923 传真: 地址:北京市海淀区西三旗上奥世纪中心A座9层906 邮编:100096